CTRI/2023/10/058221
Not yet recruiting
未知
An open-label, single-arm clinical study to evaluate the efficacy & safety of Malbet syrup in pediatric patients with uncomplicated influenza. - Nil
Solar Herbo Pvt. Ltd.0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: J118- Influenza due to unidentified influenza virus with other manifestations
- Sponsor
- Solar Herbo Pvt. Ltd.
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Male and female patients of age of 6\-12 (Both inclusive) years visiting the outpatient department of the study center;2\)Viral fever, cold, cough and pyrexia of unknown origin irrespective of the type of viral infection as per the discretion of investigator;3\)At time of enrollment has 2 or more of the following symptoms (moderate to severe in intensity based on 5\-point Linkert scale) that began 48 hours or less prior to the anticipated start of dosing with study medication: cough, sore throat, headache, nasal congestion, body aches and pains, fatigue;4\)Has a fever less than or equal to 103 °F at the first visit or in the 6 hours prior if antipyretics were taken.
Exclusion Criteria
- •1\.Patients who required hospitalization at the time of screening;
- •2\.Fever \> 103 °F;
- •3\.Has taken an anti\-influenza drug, or received any live attenuated influenza vaccine within 4 weeks prior to signing the informed consent;
- •4\.Suspected bacterial respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or infiltrate in lung observed on chest x ray, or is on antibiotics for pulmonary disease) as per discretion of investigator at the start of study;
- •5\.Patients having any congenital abnormality or epileptic attack
- •6\.Current use of adrenocorticosteroids (except topical preparation) or immunosuppressive drugs;
- •7\.Any other clinical condition which may jeopardize the study outcome or patient health in any way as per discretion of investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
A study of tacrolimus lipid suspension in adult patients of allergic conjunctivitisHealth Condition 1: H104- Chronic conjunctivitisCTRI/2021/05/033314Intas Pharmaceuticals Ltd
Not yet recruiting
Phase 3
To know the effect of Rumalaya cream in common muscular paiHealth Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissueCTRI/2021/11/038256Himalaya Wellness Company
Completed
Phase 2
A clinical study of two formulations, navakashaya and vidangadi lepa in patients with vicharchika(dermatitis).CTRI/2022/05/042516Sri Dharmasthala Manjunatheswara College of Ayurveda and Hospital30
Not yet recruiting
Not Applicable
Evaluation of Safety and Tolerability of Purim Tablet in Healthy PeopleCTRI/2022/06/043510Himalaya Wellness Company
Not yet recruiting
Phase 1
Evaluate the Safety and Tolerability of HHIC-102107 Capsules in Healthy AdultsCTRI/2023/03/051067Himalaya Wellness Company